Clinical trials: PSA Failure
Prostate Cancer
Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
The primary objective of the trial is to compare the impact and safety of delayed salvage therapy (dSRT, i.e., SRT initiated at PSA values of 0.4-0.5 ng/ml) to those of early salvage therapy (eSRT, i.e., at PSA levels of 0.2…
- Trial name
- ESTABLISH (NCT05232578)
- Testing
- Early salvage radiotherapy (eSRT), Delayed Salvage radiotherapy (dSRT)
- Volunteers
- 380 people
- Sponsor
- General University Hospital, Prague
Prostate Cancer Recurrent
Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer
This trial is a phase I open-label, single center study designed to evaluate the safety, tolerability and preliminary efficacy of the bispecific prostate specific membrane antigen (PSMA) and cluster of differentiation protein 3…
- Trial name
- ProSperACC-1 (NCT05646550)
- Testing
- CC-1 Infusion
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital Tuebingen
Prostatic Neoplasms
Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA
To determine if the oral administration of PectaSol-C Modified Citrus Pectin (MCP) is effective at improving Prostate Specific Antigen (PSA) kinetics in men with biochemical relapsed prostate cancer and serial increases in PSA…
- Trial name
- NCT01681823
- Testing
- PectaSol-C Modified Citrus Pectin (MCP)
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- EcoNugenics
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate…
- Trial name
- SABRE (NCT05407311)
- Testing
- 64Cu-SAR-BBN
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate
PROCARE - PROstate Cancer Real World Evidence Registry
The aim of this registry study with long-term follow-up is to record the course of therapy and disease in patients with recurrent and metastatic prostate cancer.
- Conditions
- Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Trial name
- PROCARE (NCT06835218)
- Where
- 53 sites in Germany
- Volunteers
- 5,000 people
- Sponsor
- UroTrials Company (GmbH)
Prostate Cancer
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
The aim of this study is to test whether adding chemotherapy/cabazitaxel and hormonal/androgen deprivation therapy before surgical removal of your prostate would improve the outcome of salvage surgery for locally recurrent…
- Trial name
- NCT01531205
- Testing
- Androgen Ablation, Cabazitaxel, Salvage Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer, Biochemical Recurrence
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with…
- Trial name
- NCT05753566
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence
The purpose of this study is to investigate if a new blood test looking at PSA and a group of PSA related proteins in a patient's blood can indicate which men after surgery with a rising PSA could benefit from treatment, and/or…
- Trial name
- NCT02070575
- Testing
- blood draw
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
68Ga-PSMA HBED-PET/CT, Prostate Cancer
68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated
Single-center, prospective, diagnostic trial in radically treated patients with biochemical recurrence of prostate cancer. Patients with radically treated prostate cancer with biochemical relapse and negativity of all traditional…
- Trial name
- GaPSMA (NCT02920229)
- Testing
- 68Ga- PSMA
- Where
- Italy
- Volunteers
- 1,230 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Radical Perineal Prostatectomy
A Capsular Incision and Biochemical Recurrence After Radical Perineal Prostatectomy
To evaluate the impact of capsular incisions on biochemical recurrence (BCR) and the potential risk factors of capsular incisions.
- Trial name
- NCT00748514
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- Samsung Medical Center
Recurrent Prostate Cancer
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
This phase II trial studies how well fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging (MRI) work in finding metastases in patients with…
- Trial name
- NCT01967862
- Testing
- computed tomography, bone scan, 3-Tesla magnetic resonance imaging
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
This study was a prospective analysis in men with localized prostate cancer who had rising Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation.
- Trial name
- IAS (NCT00223665)
- Testing
- Flutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Washington
Prostatic Neoplasm
Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
Fluciclovine F18 (Axumin) has been demonstrated to provide good delineation of recurrence of prostate cancer after definitive therapies.
- Trial name
- NCT04234399
- Testing
- Fluciclovine PET/CT using a digital PET/CT
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Vermont
Prostate Cancer
Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy
The main purpose of this study is to try to find out whether adding chemotherapy to the standard treatment for your stage of prostate cancer is more effective than the standard treatment by itself.
- Trial name
- NCT00480857
- Testing
- Docetaxel (Taxotere)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
This trial is a phase II, randomized, open label study designed to evaluate safety, tolerability and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity, and of VACXS15-PC01, a prostate cancer (PC)-specific…
- Trial name
- ImmProCure (NCT07860047)
- Testing
- PSMAxCD3, bispecific antibody CC-1, Multipeptide Vaccine VAC-XS15-PC01
- Where
- 4 sites in Germany
- Volunteers
- 84 people
- Sponsor
- University Hospital Tuebingen
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Prostate Cancer
Long-term Better Than Short-term ADT With Salvage RT
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after…
- Trial name
- LOBSTER (NCT04242017)
- Testing
- Triptoreline
- Where
- 3 sites in Belgium
- Volunteers
- 394 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications)
HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer
This is single center prospective phase 2 randomized trial aiming to compare biochemical and clinical relapse free survival and toxicity profiles of stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDRB)…
- Trial name
- NCT04870567
- Testing
- Stereotactic ablative radiotherapy, High dose rate brachytherapy
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon